bupropion has been researched along with Alcoholism in 19 studies
Bupropion: A propiophenone-derived antidepressant and antismoking agent that inhibits the uptake of DOPAMINE.
bupropion : An aromatic ketone that is propiophenone carrying a tert-butylamino group at position 2 and a chloro substituent at position 3 on the phenyl ring.
Alcoholism: A primary, chronic disease with genetic, psychosocial, and environmental factors influencing its development and manifestations. The disease is often progressive and fatal. It is characterized by impaired control over drinking, preoccupation with the drug alcohol, use of alcohol despite adverse consequences, and distortions in thinking, most notably denial. Each of these symptoms may be continuous or periodic. (Morse & Flavin for the Joint Commission of the National Council on Alcoholism and Drug Dependence and the American Society of Addiction Medicine to Study the Definition and Criteria for the Diagnosis of Alcoholism: in JAMA 1992;268:1012-4)
Excerpt | Relevance | Reference |
---|---|---|
"This is a double-blind placebo-controlled study of sustained-release bupropion as a smoking cessation aid in alcoholics undergoing treatment for their alcoholism." | 9.12 | Bupropion and nicotine patch as smoking cessation aids in alcoholics. ( Agrawal, S; Grant, KM; Kelley, SS; Meyer, JR; Romberger, DJ; Smith, LM, 2007) |
"To evaluate the efficacy of bupropion for smoking cessation in smokers with a former history of major depression or alcoholism, and changes in depressive symptoms during smoking abstinence." | 9.09 | Efficacy of bupropion for smoking cessation in smokers with a former history of major depression or alcoholism. ( Croghan, IT; Glover, ED; Hayford, KE; Hurt, RD; Offord, KP; Patten, CA; Rummans, TA; Sachs, DP; Schroeder, DR, 1999) |
"Smoking cessation trials of sustained-release bupropion (bupropion SR) were initially conducted in a general population of smokers who were motivated to quit smoking." | 8.81 | Use of sustained-release bupropion in specific patient populations for smoking cessation. ( Tonstad, S, 2002) |
"This is a double-blind placebo-controlled study of sustained-release bupropion as a smoking cessation aid in alcoholics undergoing treatment for their alcoholism." | 5.12 | Bupropion and nicotine patch as smoking cessation aids in alcoholics. ( Agrawal, S; Grant, KM; Kelley, SS; Meyer, JR; Romberger, DJ; Smith, LM, 2007) |
"To evaluate the efficacy of bupropion for smoking cessation in smokers with a former history of major depression or alcoholism, and changes in depressive symptoms during smoking abstinence." | 5.09 | Efficacy of bupropion for smoking cessation in smokers with a former history of major depression or alcoholism. ( Croghan, IT; Glover, ED; Hayford, KE; Hurt, RD; Offord, KP; Patten, CA; Rummans, TA; Sachs, DP; Schroeder, DR, 1999) |
" In the United States there are medications available to treat tobacco use disorders (nicotine replacement, bupropion, and varenicline), alcohol use disorders (naltrexone and acamprosate), and opioid use disorders (methadone and buprenorphine)." | 4.93 | Pharmacotherapy for Substance Use Disorders. ( Klein, JW, 2016) |
"Alcoholism and nicotine dependence share many neurobiological underpinnings; the presence of one drug can cause a person to crave the other." | 4.83 | Treating smoking dependence in depressed alcoholics. ( Ait-Daoud, N; Breland, AB; Johnson, BA; Lynch, WJ; Marzani-Nissen, GR; Penberthy, JK, 2006) |
" Although alcoholism has received the most attention, nicotine, heroin, and cocaine have all been shown to be influenced by heredity." | 4.82 | Anticraving medications for relapse prevention: a possible new class of psychoactive medications. ( O'Brien, CP, 2005) |
"Smoking cessation trials of sustained-release bupropion (bupropion SR) were initially conducted in a general population of smokers who were motivated to quit smoking." | 4.81 | Use of sustained-release bupropion in specific patient populations for smoking cessation. ( Tonstad, S, 2002) |
"Treatment with bupropion SR among abstinent alcoholic smokers did not delay relapse or result in improved long-term smoking abstinence." | 2.74 | A randomized, controlled trial of bupropion sustained-release for preventing tobacco relapse in recovering alcoholics. ( Croghan, IT; Decker, PA; Hays, JT; Hurt, RD; Offord, KP; Patten, CA, 2009) |
"Guidance on Major Depressive Disorder (MDD) treatment in those with comorbid Alcohol Use Disorder (AUD) is limited." | 1.91 | Treatment outcomes in major depressive disorder in patients with comorbid alcohol use disorder: A STAR*D analysis. ( Blumberger, DM; Daskalakis, ZJ; Jones, BDM; Le Foll, B; Sloan, ME; Tang, VM; Voineskos, D; Wang, G; Weissman, CR; Yu, D, 2023) |
"fluoxetine treatment induced a long-lasting increase in alcohol consumption during relapse, an effect that was not observed in the case of bupropion treatment." | 1.51 | Bupropion, a possible antidepressant without negative effects on alcohol relapse. ( Alen, F; Antón, M; Arco, R; Ballesta, A; de Fonseca, FR; de Heras, RG; Nogueira-Arjona, R; Orio, L; Pavón, FJ; Ramírez-López, M; Romero-Sanchiz, P; Serrano, A; Suárez, J; Vargas, A, 2019) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 3 (15.79) | 18.2507 |
2000's | 8 (42.11) | 29.6817 |
2010's | 4 (21.05) | 24.3611 |
2020's | 4 (21.05) | 2.80 |
Authors | Studies |
---|---|
Tang, VM | 1 |
Yu, D | 1 |
Weissman, CR | 1 |
Jones, BDM | 1 |
Wang, G | 1 |
Sloan, ME | 1 |
Blumberger, DM | 1 |
Daskalakis, ZJ | 1 |
Le Foll, B | 1 |
Voineskos, D | 1 |
Deng, X | 1 |
Shang, X | 1 |
Guo, K | 1 |
Zhou, L | 1 |
Wang, Y | 1 |
Wu, Y | 1 |
Liang, S | 1 |
E, F | 1 |
Liu, W | 1 |
Wang, Z | 1 |
Li, X | 1 |
Yang, K | 1 |
Rábade-Castedo, C | 1 |
de Granda-Orive, JI | 1 |
Riesco-Miranda, JA | 1 |
De Higes-Martínez, E | 1 |
Ramos-Pinedo, Á | 1 |
Cabrera-César, E | 1 |
Signes-Costa Miñana, J | 1 |
García Rueda, M | 1 |
Pastor-Esplá, E | 1 |
Jiménez-Ruiz, CA | 1 |
Swinford-Jackson, SE | 1 |
O'Brien, CP | 2 |
Kenny, PJ | 1 |
Vanderschuren, LJMJ | 1 |
Unterwald, EM | 1 |
Pierce, RC | 1 |
Ballesta, A | 1 |
Orio, L | 1 |
Arco, R | 1 |
Vargas, A | 1 |
Romero-Sanchiz, P | 1 |
Nogueira-Arjona, R | 1 |
de Heras, RG | 1 |
Antón, M | 1 |
Ramírez-López, M | 1 |
Serrano, A | 1 |
Pavón, FJ | 1 |
de Fonseca, FR | 1 |
Suárez, J | 1 |
Alen, F | 1 |
Klein, JW | 1 |
Hays, JT | 1 |
Hurt, RD | 2 |
Decker, PA | 1 |
Croghan, IT | 2 |
Offord, KP | 2 |
Patten, CA | 2 |
Saracino, MA | 1 |
Marcheselli, C | 1 |
Somaini, L | 1 |
Gerra, G | 1 |
De Stefano, F | 1 |
Pieri, MC | 1 |
Raggi, MA | 1 |
Karam-Hage, M | 1 |
Strobbe, S | 1 |
Robinson, JD | 1 |
Brower, KJ | 1 |
Tonstad, S | 1 |
Bagley, SC | 1 |
Yaeger, D | 1 |
Doran, CM | 1 |
Duszynski, KM | 1 |
Beilby, JJ | 1 |
Mattick, RP | 1 |
Ait-Daoud, N | 1 |
Lynch, WJ | 1 |
Penberthy, JK | 1 |
Breland, AB | 1 |
Marzani-Nissen, GR | 1 |
Johnson, BA | 1 |
Grant, KM | 1 |
Kelley, SS | 1 |
Smith, LM | 1 |
Agrawal, S | 1 |
Meyer, JR | 1 |
Romberger, DJ | 1 |
Nunes, EV | 1 |
McGrath, PJ | 1 |
Quitkin, FM | 1 |
Litten, RZ | 1 |
Allen, JP | 1 |
Hayford, KE | 1 |
Rummans, TA | 1 |
Schroeder, DR | 1 |
Glover, ED | 1 |
Sachs, DP | 1 |
Sullivan, MA | 1 |
Covey, LS | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Pharmacologic Relapse Prevention for Alcoholic Smokers[NCT00000457] | Phase 2 | 195 participants (Actual) | Interventional | 1998-06-30 | Completed | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
9 reviews available for bupropion and Alcoholism
Article | Year |
---|---|
Efficacy and safety of antidepressants for smoking cessation: A systematic review and network meta-analysis.
Topics: Alcoholism; Antidepressive Agents; Bupropion; Humans; Network Meta-Analysis; Nortriptyline; Smoking; | 2023 |
Clinical Practice Guideline of Spanish Society of Pneumology and Thoracic Surgery (SEPAR) on Pharmacological Treatment of Tobacco Dependence 2023.
Topics: Adolescent; Alcoholism; Bupropion; Female; Humans; Nicotinic Agonists; Pregnancy; Pulmonary Medicine | 2023 |
Pharmacotherapy for Substance Use Disorders.
Topics: Age Factors; Alcohol Deterrents; Alcoholism; Antidepressive Agents; Buprenorphine; Bupropion; Drug T | 2016 |
Use of sustained-release bupropion in specific patient populations for smoking cessation.
Topics: Alcoholism; Body Weight; Bupropion; Delayed-Action Preparations; Depression; Dopamine Uptake Inhibit | 2002 |
Anticraving medications for relapse prevention: a possible new class of psychoactive medications.
Topics: Alcoholism; Behavior, Addictive; Bupropion; Cocaine-Related Disorders; Disulfiram; Humans; Naltrexon | 2005 |
Treating smoking dependence in depressed alcoholics.
Topics: Alcoholism; Antidepressive Agents; Bupropion; Clinical Trials as Topic; Cognitive Behavioral Therapy | 2006 |
Treating anxiety in patients with alcoholism.
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Alcoholism; Antidepressive Agents; Anxiety Disorders | 1995 |
Medications for alcohol, illicit drug, and tobacco dependence. An update of research findings.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Buprenorphine; Bupropion; Forecasting; Humans; Methadyl | 1999 |
Nicotine dependence: the role for antidepressants and anxiolytics.
Topics: Alcoholism; Anti-Anxiety Agents; Antidepressive Agents; Anxiety Disorders; Attention Deficit Disorde | 2002 |
5 trials available for bupropion and Alcoholism
Article | Year |
---|---|
A randomized, controlled trial of bupropion sustained-release for preventing tobacco relapse in recovering alcoholics.
Topics: Adult; Aged; Alcoholism; Bupropion; Delayed-Action Preparations; Dopamine Uptake Inhibitors; Double- | 2009 |
Bupropion-SR for smoking cessation in early recovery from alcohol dependence: a placebo-controlled, double-blind pilot study.
Topics: Alcoholism; Bupropion; Delayed-Action Preparations; Dopamine Uptake Inhibitors; Double-Blind Method; | 2011 |
Hyponatremia associated with bupropion, a case verified by rechallenge.
Topics: Alcoholism; Antidepressive Agents, Second-Generation; Bipolar Disorder; Bupropion; Cocaine-Related D | 2005 |
Bupropion and nicotine patch as smoking cessation aids in alcoholics.
Topics: Administration, Cutaneous; Adult; Alcoholism; Bupropion; Community Health Services; Delayed-Action P | 2007 |
Efficacy of bupropion for smoking cessation in smokers with a former history of major depression or alcoholism.
Topics: Adult; Alcoholism; Antidepressive Agents, Second-Generation; Bupropion; Delayed-Action Preparations; | 1999 |
5 other studies available for bupropion and Alcoholism
Article | Year |
---|---|
Treatment outcomes in major depressive disorder in patients with comorbid alcohol use disorder: A STAR*D analysis.
Topics: Alcoholism; Antidepressive Agents; Bupropion; Comorbidity; Depressive Disorder, Major; Humans; Treat | 2023 |
The Persistent Challenge of Developing Addiction Pharmacotherapies.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Bupropion; Central Nervous System Stimulants; Cocaine-R | 2021 |
Bupropion, a possible antidepressant without negative effects on alcohol relapse.
Topics: Alcohol Drinking; Alcoholism; Animals; Antidepressive Agents, Second-Generation; Bupropion; Dopamine | 2019 |
Simultaneous determination of disulfiram and bupropion in human plasma of alcohol and nicotine abusers.
Topics: Alcoholism; Bupropion; Chromatography, High Pressure Liquid; Disulfiram; Humans; Molecular Structure | 2010 |
Use of pharmacotherapies for the management of addictive behaviours in Australian clinical practice.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Australia; Bupropion; Dopamine Uptake Inhibitors; Femal | 2006 |